Search alternatives:
significant benefits » significant effects (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant risk » significant role (Expand Search)
Showing 1 - 20 results of 21,342 for search '(( ((significant benefits) OR (significant risk)) decrease ) OR ( significant decrease decrease ))', query time: 0.64s Refine Results
  1. 1
  2. 2

    Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…<p>Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.…”
  3. 3

    HFD decreases intermediate-term memory. by Tong Yue (6033305)

    Published 2025
    “…(C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”
  4. 4

    Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…The red line represents the significance threshold (<i>P < </i>5 × 10<sup>−8</sup>). …”
  5. 5

    HFD decreases ITM and alters metabolic homeostasis. by Tong Yue (6033305)

    Published 2025
    “…Two-way ANOVA, n.s., not significant, ** p < 0.01). <b>(F)</b> Long-term memory (LTM) was significantly decreased in the HFD group. …”
  6. 6

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  12. 12

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  13. 13

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  14. 14
  15. 15

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
  16. 16

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
  17. 17
  18. 18
  19. 19
  20. 20